
    
      Eligible patients will be treated with 4 µg GAD-Alum into an inguinal lymph gland at three
      occasions, with one month intervals in combination with Vitamin D (14 000 IU/week) for 4
      months, starting 1 month prior to first GAD-Alum injection.

      A sub-study will include three adult patients from the main study and evaluate safety after a
      fourth injection with 4 μg GAD-Alum into an inguinal lymph gland in combination with oral
      vitamin D intake. The Prolonged Extension Study Period is 12 months and will start 30,5
      months after baseline.
    
  